Compound selection drug properties

An analysis of the solubility and absorption rates for the 254 drugs considered here shows that the 25 compounds fulfilling the condition of 0.25a - XQ > 5.0 and HQi > 20.0 have solubility of only a few micrograms per milHHter, and are absorbed at the level of only a few percents. Such properties are too poor for drug development, so these parameters can be useful as an alert in computer-aided compound selection. 

In summary, such simple classification schemes for drug-likeness can, in a very fast and robust manner, help to enrich compound selections with drug-like molecules. These filters are very general and cannot be interpreted any further. Thus, they are seen rather as a complement to the more in-depth profiling of leads and drugs by using molecular properties and identifying trends in compound series. 

Application of ultra-high-throughput in silico estimation of biopharmaceutical properties to the generation of rule-based computational alerts has the potential to improve compound selection to those drug candidates that are likely to prove less troublesome in their development. The extension of purely in silico methods to the realm of mechanistic simulation further enhances our ability to predict the impact of physiological and biochemical process on drug absorption and bioavailability. 

There are a variety of structural classes of compounds that are active against each phosphodiesterase, and evidence suggests that selective inhibitors of PDEs can be identified. The structural diversity of PDE inhibitors provides a multitude of opportunities for development of compounds with drug-like properties. Furthermore, phosphodiesterase inhibition, which avoids direct interaction of a compound with a cell surface or nuclear receptor, may circumvent some of the target selectivity issues that can complicate receptor-based therapeutic approaches. As noted above, the specific subcellular distribution of phosphodiesterase enzymes is a key feature of their ability to modulate intracellular signaling pathways. This localization of the enzyme may minimize non-specific target... 

The determination of endogenous compounds and drugs in biological matrices has always presented a formidable challenge as one has to consider various factors before attempting to develop a suitable HPLC assay. These include the physicochemical properties of the compound such as the pKa value, solubility, volatility, particular functional groups (e.g., possessing chromophores, fluorophores, or electroactive characteristics), potential metabolites, and the required sensitivity and specificity. All these aspects will determine the type of extraction processes, analytical column selection, and suitable detector systems to be used as part of the HPLC apparatus. 

While not convincing from a statishcal perspective, the results in this section are consistent with a trend high-activity molecules published in the past decade of medicinal chemistry literature are more likely to be found in the large, hydrophobic and poor solubility corner of chemical property space. These results are not consistent with, for example, cell-based [41] and median-based [42] partihoning of biologically active compounds however, such analyses were performed in the presence of inactive compounds selected from MDDR[41] or ACD [42], with quite probably unrelated chemotypes. ACD, the Available Chemicals Directory [43], and MDDR, the MDL Drug Data Report [43], are databases commonly used by the pharmaceuhcal industry. 

Figure 6. Distributions of essential computed molecular properties defining drug-likeness for selected compound sets. Shown are the fraction of compounds vs. the properties. Orange NIBR historical medicinal chemistry collection. Brown Compilation of combinatorial chemistry libraries. Dark Green Drugs (launched or Phase III listed in MDDR or CMC). Brown Compilation from combinatorial libraries. Pink Natural products of DNP. tight Green HTS hits of NIBR 2004 screens. All properties were calculated with Pipeline Pilot software www.scitegic.com).

Nine examples of the successful application of property-based QSARs to drug design have been discussed by Fujita (1990). In three of these examples, compounds selected on the basis of QSARs have been marketed. 

These results are clear evidence that sulfur reacts mainly directly with Pt amine compounds, substituting Cl-, without prior aquation. As is evident from Table IV, the hydrolyzed species [Pt(dien)(H20)]2+ will almost selectively react with 5 -GMP (3.6 Af-1 sec-1 versus 0.51 Af-1 sec-1 and 0.18 Af-1 sec-1), whereas the chloro species [Pt(dien)Cl]+ will only react with sulfur. This information is of extreme importance in the strategy of the development of new Pt drugs. If it would be possible to develop a compound with structural properties such that the direct attack by sulfur is inhibited, but with a similar rate of chloro hydrolysis compared to cis-Pt, this would lead to compounds with improved antitumor properties and lower toxicities. The data depicted in Table IV were obtained at pH 5. However, it has been proved that GS- reacts remark-... 

The goal ofthe formulation scientist at this stage is to support the candidate selection process by understanding key physicochemical properties and other factors that can affect the delivery and exposure of compounds. Through well designed and executed formulation work, the formulation support helps to select drug candidates with appropriate physicochemical properties to ensure the developability... 

Another feasible approach would be to screen all compounds for pharmacokinetic properties, and then only select drug candidates from compounds existing in pharmacokinetically viable chemistry space, (Lipinski, 2000). 

---